Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

L Klimek1, A M Chaker2, M Cuevas3

  • 1Zentrum für Rhinologie und Allergologie, Wiesbaden.

Laryngo- Rhino- Otologie
|January 22, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Graphene-plasmon-mediated coherent dynamics in an N-quantum-emitter system.

Optics express·2026
Same author

Correspondence: The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Urticaria, and Chronic Rhinosinusitis With Nasal Polyps.

Allergy·2026
Same author

[Use of Omalizumab-biosimilars for CRSwNP in the German Health Care System - a Position Paper of the German Societies for Allergy AeDA and ORL DGHNO-KHC].

Laryngo- rhino- otologie·2026
Same author

Correspondence: First Peanut (Arachis hypogaea) Allergen Oral Immunotherapy Product Out of Sale-A Major Drawback for Food Allergy Immunotherapy?

Allergy·2026
Same author

[Different immunological types of CRSwNP in the context of the new European EAACI nomenclature : Part 3: Hypersensitivity reactions of type VI].

HNO·2026
Same author

The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways-An EAACI Position Paper.

Allergy·2026
Same journal

Guideline-Based Cochlear Implant Care: A Model for Structuring Delegated Technical Aftercare.

Laryngo- rhino- otologie·2026
Same journal

Audiometric evaluation and quality-of-life in OSIA users - a retrospective monocentric study.

Laryngo- rhino- otologie·2026
Same journal

[Diagnosis and treatment of vestibular migraine - recent developments and future treatment strategies].

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
Same journal

Laryngo- rhino- otologie·2026
See all related articles

Two new RNA vaccines for COVID-19 have raised concerns about rare anaphylaxis cases, potentially linked to polyethylene glycols (PEGs). This series addresses diagnosis and treatment for vaccine allergies.

Area of Science:

  • Immunology
  • Vaccinology
  • Allergology

Background:

  • Conditional approval of BNT162b2 and mRNA-1273 RNA vaccines against SARS-COV2 in the European Community.
  • Emergence of rare anaphylaxis cases post-vaccination with novel RNA vaccine compounds.
  • Identification of polyethylene glycols (PEGs) as potential allergens in mRNA COVID-19 vaccines.

Purpose of the Study:

  • To summarize current pathophysiological and clinical information regarding potential allergies to mRNA COVID-19 vaccines.
  • To describe the characteristics of the approved RNA vaccines.
  • To provide practical guidance for the diagnosis and treatment of suspected allergies to mRNA COVID-19 vaccines.

Main Methods:

  • Literature review of existing pathophysiological and clinical data.

Related Experiment Videos

  • Analysis of vaccine characteristics, including excipient profiles.
  • Development of diagnostic and therapeutic recommendations.

    • Main Results:

    • Polyethylene glycols (PEGs) are identified as likely culprits in rare anaphylactic reactions to mRNA COVID-19 vaccines.
    • Understanding vaccine composition is crucial for identifying potential allergens.
    • Clinical presentation and management strategies for vaccine-induced anaphylaxis are outlined.

    Conclusions:

    • Anaphylaxis following mRNA COVID-19 vaccination is rare but warrants attention.
    • Polyethylene glycols (PEGs) are implicated, necessitating awareness among healthcare providers and patients.
    • This series provides essential information for managing potential allergic reactions to mRNA COVID-19 vaccines.